6-KThe Wire
HUTCHMED (China) Ltd files 6-K
Filed Jun 25, 2026 · 8d ago · Accession 0001648257-26-000041
Plain English
Hutchmed (China) Limited announced pivotal Phase II data for fanregratinib in intrahepatic cholangiocarcinoma, presented at the ESMO Gastrointestinal Cancers Congress 2026.
Filing details
- Company
- HUTCHMED (China) Ltd
- Ticker
- HCM
- CIK
- 1648257
- Form type
- 6-K
- Filing date
- Jun 25, 2026
- Report date
- Jun 25, 2026
- Document
- hcm-20260625x6k.htm
- Size
- 57 KB